---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-051191"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:53:05.285025+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 shows copper-binding ability; Wilson's disease program advanced

## Summary
- Preclinical studies show Telomir-1 strongly binds copper, targeting Wilson's disease caused by copper accumulation.
- Company plans IND/INAD submission by Q4 2025, with clinical trials expected in 2026.
- Telomir-1 also interacts with essential ions, potentially improving on current Wilson's treatments.
- Telomir is advancing preclinical studies in Wilson's disease while exploring other copper-related conditions.

## SEC filing metadata
- accession: 0001493152-24-051191
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315224051191/0001493152-24-051191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315224051191/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-051191
- JSON: https://secwatch.observer/filing/0001493152-24-051191.json
- Plain text: https://secwatch.observer/filing/0001493152-24-051191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.